Annual Product Review Process For Pharma Industry Part1
Annual Product Review Process For Pharma Industry Part1
Annual Product Review Process For Pharma Industry Part1
Applies to:
SAP Service Oriented Architecture (SOA), Business Process Management (BPM), Business Process Expert
(BPX) and Life-Sciences Industry Vertical. For more information, visit the Business Process Expert
homepage.
Summary
For Life-Sciences Industry, Annual Product Review (APR) is an important part of the overall regulatory
compliance process. This article will provide an overview about APR and typical challenges faced by the
customers. We also share the experiences from a Collaboration Project between SAP ES Community and
Intelligroup, where APR Community Definition Group (CDG) was formed as part of this initiative and multiple
work packages were defined and validated by customers as part of this innovation project. We intend to
cover this topic in 3 parts and beginning with this as the first one focusing on general overview. The next
articles will cover the high level work package descriptions and the use of SAP BPM and other tools to build
this composite solution.
Author Bio
Y Vinesh Balakrishnan is a Domain Expert in Life Sciences, currently working at Intelligroup. He is a
business process expert with a proven ability to adopt technology in innovative manner to meet business
process requirements and solve business problems, with a sharp focus on execution excellence. He is a
member of Enterprise Services Community and currently working on solutions in the areas of Annual Product
Review, Validation and A1 Solution for Life Sciences companies.
Liladhar Bagad is an Enterprise Architect, currently working at Intelligroup. He has worked with many
Fortune 500 customers in successful implementations and supporting their key business processes using the
state of the art technology. He is an active member of Enterprise Services Community and holds a proven
thought leadership in BPM and SOA.
Table of Contents
Introduction to APR Process...............................................................................................................................3
Process Flow...................................................................................................................................................3
APR Solution – Our Vision for Composite Application .......................................................................................3
Summary.............................................................................................................................................................4
Silent Features of the APR Composite ........................................................................................................................4
Business Value from APR Composite..........................................................................................................................4
Related Content..................................................................................................................................................5
Disclaimer and Liability Notice............................................................................................................................6
Process Flow
APR provides very effective tools to look back on product performance to determine if changes are needed.
An effective APR process would help to fine tune the product specification, ensure that changes made to the
manufacturing or control processes are effective and/or ascertain further changes, establish the need for
validation or revalidations, identify improvement opportunities, provides a high level view to understand the
cumulative effects of several small changes and a possible negative effect and lastly, it provides a good tool
for the management to take cognizance of concerns or areas that require corrective or preventive actions.
Like any good governance or quality management process, management commitment and belief in the
effectiveness of an APR process and the benefits arising from an effective APR, the APR process would
suffer. When FDA cites APR deficiencies, it assigns the responsibility to the management.
report as requested by FDA in the areas of: Recommendations from prior APR report, Batches
manufactured, Batches rejected, Batches reworked/reprocessed, Deviations, Out of Specification Results
(OOS),Environmental monitoring data, Product Specification/Method Changes, Retain samples, Changes
effected (Change Control),Analytical data, Validation review, Recalls, Customer Complaints and Returns,
Adverse Drug events ,Inspections from any official inspectorate and New recommendations.
APRs can be organized in a variety of ways. Some firms assemble comprehensive and detailed APRs that
can comprise several hundred pages each. Others collect only minimal data and include extensive
summaries of data. Any of the approaches can meet the regulatory expectations / GMP requirements if the
minimum information required is included.
Design approach enables the deployments of the solution in several ways thereby improving productivity as
well as the ability to draw a larger resource pool in the compilations. Additional elements or areas that may
emerge can be easily incorporated. Although the current design, envisages the use of the ERP system, the
team recognizes that in the actual eco system organization may be using several system for the areas.
Design approach looks to use the standard SAP functionalities or features thereby ensuring minimal
development requirements, consistency with the SAP architecture, no additional skill sets to be learnt by the
IT personnel and more importantly leverages the Audit Trail and electronic signatures. Usage and
assignment of roles enhance the access and authorization levels.
Summary
Silent Features of the APR Composite
• This solution streamlines and optimizes the process of compiling the Annual Product Review
(APR)
• It will support a mainly semi- automated process of compiling an Annual Product Review report
and it’s tracking and tracing throughout the compilation process from scheduling to publication of
the approved APR.
• The target market is the Pharmaceutical and Biopharmaceutical companies using the SAP ERP
system.
• The solution will be a composite based on NW Composition Environment CE 7.1, will use SAP
BPM functionality from EhP1 and mainly consuming backend ERP service operations from
Enhancement Package 3.
As this program is launched through SAP ES Community, we have created a workspace PCDG 76 Annual
Product Review for this group. Interested participants can request to join this group based on their
requirements. We look forward to your participation and active contribution towards making this effort a
successful one for Life-Sciences companies.
Related Content
Please refer to the following content for further details. This will definitely help you to get ready for our next
article in this series.
PCDG 76 Annual Product Review
Code of Federal Regulations 21 CFR 211.180 (e)
SAP NetWeaver BPM
APR SOP Sample I
APR SOP Sample II
For more information, visit the Business Process Expert homepage.